SCHEMBL289065

SCHEMBL289065

COc1ccccc1-n1cccc1P(C1CCCCC1)C1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPGD P15428 2/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 2/20 0.37
DRD2 P14416 2/20 0.37
DRD3 P35462 2/20 0.37
MAPT P10636 1/20 0.37
SLC18A3 Q16572 1/20 0.37
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
ADRB1 P08588 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTR3A P46098 1/20 0.36
HTR6 P50406 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
SIGMAR1 Q99720 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29732987 1.00 GAA (0.46) GAASMN1; SMN2L3MBTL1HPGDHTT
SCHEMBL15890588 0.82 TSHR (0.38) SMN1; SMN2L3MBTL1HPGDNPSR1ALDH1A1
SCHEMBL15921413 0.78 SMN1; SMN2 (0.48) GAASMN1; SMN2L3MBTL1HPGDHTT
SCHEMBL4319027 0.77 DDAH1 (0.35) SMN1; SMN2HPGDALDH1A1MAPTHTR3E
SCHEMBL16449094 0.76 GAA (0.55) GAAHPGDALDH1A1DRD2DRD3
SCHEMBL16351498 0.76 EPHX1 (0.33) SMN1; SMN2L3MBTL1HPGDALDH1A1
SCHEMBL289929 0.75 KDM4E (0.42) GAASMN1; SMN2L3MBTL1HTTNPSR1
SCHEMBL27631126 0.75 FGFR1 (0.40) SMN1; SMN2HPGDALDH1A1DRD2DRD3
SCHEMBL20994196 0.73 KDM4E (0.40) GAASMN1; SMN2L3MBTL1HTTNPSR1
SCHEMBL29370031 0.73 GAA (0.51) GAASMN1; SMN2HPGDALDH1A1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427468-B2 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PLC (GB) 2025-06-04 EP claimed
EP-4267591-A2 ORGANOMETALLIC COMPOUNDS Umicore AG & Co. KG (DE) 2023-11-01 EP claimed
CN-116802187-A Organometallic compounds 优米科尔股份公司及两合公司 2023-09-22 CN claimed
WO-2022136049-A2 ORGANOMETALLIC COMPOUNDS UMICORE AG & CO. KG (DE) 2022-06-30 WO claimed
CN-105111132-B One kind 2,2 ' joins the production method of carbazole 河南省科学院化学研究所有限公司 2017-11-03 CN claimed
EP-2427468-B1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PLC (GB) 2017-06-14 EP claimed
EP-2951188-B1 PHOSPHORUS LIGANDS AND METHOD FOR THE SELECTIVE RUTHENIUM-CATALYZED HYDROAMINOMETHYLATION OF OLEFINS EVONIK DEGUSSA GMBH (DE) 2017-05-10 EP claimed
EP-2975019-A1 RUTHENIUM CATALYZED HYDROAMINOMETHYLATION Evonik Degussa GmbH (DE) 2016-01-20 EP claimed
WO-2015063543-A1 HYDRIDOPALLADIUM(II) HALIDES AS PREFORMED CATALYSTS FOR SUZUKI-MIYAURA CROSS-COUPLING REACTIONS LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2015-05-07 WO claimed
US-8772520-B2 Preparation of a metal complex JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2014-07-08 US claimed
US-20120116109-A1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-05-10 US claimed
EP-2427468-A1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-03-14 EP claimed
WO-2010128316-A1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2010-11-11 WO claimed
US-20100221647-A1 PYRROLE CONTAINING PHOTOCONDUCTORS XEROX CORPORATION (US) 2010-09-02 US claimed
EP-2427468-B2 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PLC (GB) 2025-06-04 EP disclosed
WO-2025016436-A1 PREPARATION METHOD FOR KRAS INHIBITOR, INTERMEDIATE THEREOF AND PREPARATION METHOD FOR INTERMEDIATE THEREOF 上海济煜医药科技有限公司 2025-01-23 WO disclosed
US-20240317779-A1 METAL COMPLEXES HAVING 4-H,6-H OR 8-H DIHYDROAZULENYL LIGANDS AND USE THEREOF UMICORE AG & CO. KG (DE) 2024-09-26 US disclosed
US-20070123707-A1 Nitrogen-containing monodentate phosphines and their use in catalysis DEGUSSA AG (DE) 2007-05-31 US disclosed
EP-1625133-A2 NITROGEN-CONTAINING MONODENTATE PHOSPHINES AND THEIR USE IN CATALYSIS Degussa AG (DE) 2006-02-15 EP disclosed
WO-2004101581-A2 NITROGEN-CONTAINING MONODENTATE PHOSPHINES AND THEIR USE IN CATALYSIS DEGUSSA AG (DE) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123707-A1 Nitrogen-containing monodentate phosphines and their use in catalysis HDHD5, PNP, PHOSPHO1 GAA 3420/4885SMN1; SMN2 4717/4885L3MBTL1 4476/4885
US-20240317779-A1 METAL COMPLEXES HAVING 4-H,6-H OR 8-H DIHYDROAZULENYL LIGANDS AND USE THEREOF DOHH, CPNE4, MDH2 GAA 2982/4885SMN1; SMN2 4589/4885L3MBTL1 4450/4885
US-20120116109-A1 PREPARATION OF A METAL COMPLEX PDCD1LG2, CD274, PDCD2L GAA 4147/4885SMN1; SMN2 2431/4885L3MBTL1 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.